{
    "Trade/Device Name(s)": [
        "MammaPrint\u00ae FFPE"
    ],
    "Submitter Information": "Agendia NV",
    "510(k) Number": "K141142",
    "Predicate Device Reference 510(k) Number(s)": [
        "K101454"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "December 8, 2014",
    "Summary Letter Received Date": "December 10, 2014",
    "Submission Date": "January 22, 2015",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene Expression Profiling Test System for Breast Cancer Prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "genetic molecular"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [
        "Formalin-fixed paraffin embedded (FFPE) breast cancer tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Diagnostic microarray",
        "Microarray scanners (serial numbers US810R3210, US22502555, US811R3213, US45103019)"
    ],
    "Method(s)/Technology(ies)": [
        "Microarray-based gene expression analysis",
        "RNA isolation",
        "Reverse transcription",
        "cDNA amplification",
        "Hybridization",
        "Feature extraction"
    ],
    "Methodologies": [
        "Gene expression profiling",
        "Microarray analysis"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Agendia MammaPrint FFPE microarray-based gene expression profiling test for breast cancer prognosis using FFPE tissue.",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test for breast cancer patients (Stage I or II, tumor \u22645 cm, lymph node negative) to assess 5-year risk of distant metastasis using FFPE tissue, for use as a prognostic marker by physicians with other clinico-pathological factors.",
    "fda_folder": "Immunology"
}